SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Injective taken over by the community.

Nonja

NONJA is trending as a top meme coin on the Injective blockchain, driven by its resilient, unruggable nature and dedicated community. Enthusiasts view it as a leveraged bet on $INJ's significant undervaluation, strong fundamentals, and anticipated institutional interest via upcoming staked ETFs.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following FDA approval of BYSANTI for bipolar I disorder and schizophrenia, which the community views as a major rerating event due to its patent protection until 2044. This, combined with the perceived "mega blockbuster" potential of Tradipitant for GLP-1 induced nausea, is fueling discussions of significant undervaluation and strong buyout speculation among big pharma.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

QQQI is a major talking point for income-focused investors due to its robust monthly dividend yield and tax-efficient Return of Capital distributions, positioning it as a preferred 'cash machine' for retirement strategies that navigate market volatility.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is trending as a "SaaSpocalypse" narrative, driven by fears that AI models like Anthropic's Claude will disrupt and replace traditional software, has led to a significant sell-off. However, the community widely views this as an illogical overreaction, asserting that established software companies will integrate AI to enhance their strong fundamentals, rather than be displaced.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy ($SWEAT) is actively trending as community members discuss its current low valuation, with many expressing long-term optimism and encouraging accumulation while highlighting its 'move-to-earn' utility where users earn crypto through physical activity and can utilize or stake their tokens for rewards.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb is gaining attention following its strong Q4 earnings and upbeat 2026 guidance, with community discussion highlighting its promising new multiple myeloma therapy's FDA priority review and its appeal as a defensive dividend stock balancing legacy product declines.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is a top discussion amid its government-funded edge AI autonomous security project and recent earnings, sparking intense debate as bulls highlight its low-power Gemini-II chip advantages for defense while skeptics raise concerns over alleged misleading performance claims and a securities fraud investigation.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is actively discussed as investors await a crucial Supreme Court tariff ruling and process recent softer inflation data, which, alongside strong Treasury auction demand, intensifies community expectations for Fed rate cuts and reinforces its appeal as a flight-to-safety asset.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics is trending after the FDA extended the PDUFA review timeline for its FSGS drug, FILSPARI, to April 13, 2026, classifying the company's responses to information requests as a "Major Amendment." While this news led to a significant share price drop, the community is deeply divided on its implications. Investors are actively debating whether this extension, without safety concerns, increases the likelihood of eventual approval by allowing further data characterization, or if it signals prolonged uncertainty for the rare kidney disease treatment.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is trending as the community fiercely debates recent FDA feedback indicating its AMT-130 data for Huntington's disease may not fully support a Biologics License Application, fueling speculation over regulatory inconsistency and discussions on the company's path forward amidst a challenging biotech landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Good Works II Acquisition Corp. operates as a blank check company which was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination. The company was founded on July 27, 2020 and is headquartered in Houston, TX.

GWII
Good Works II Acquisition Corp

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest GWII News

GWIIGood Works II Acquisition Corp